NeoPath expands share of US market for Pap smears
This article was originally published in Clinica
Executive Summary
NeoPath, the manufacturer of the AutoPap primary screening system for cervical cancer, has formed supply agreements with SmithKline Beecham and Kaiser Permanente. The company says that, with the two deals, it will have nearly 15% of the market for bulk testing of Pap smears in the US.